Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?

Background: Circulating tumor cell (CTC) counting may be a useful non-invasive biomarker that helps patients choose first-line treatment options. Nevertheless, the cost of CTC inspection may impose an economic burden on patients, necessitating the simultaneous consideration of both its clinical effe...

Full description

Bibliographic Details
Main Authors: Huiting Lin, Wenhua Wu, Xiaoya Lou, Yiming Wang, Hong Sun, Jiaqin Cai, Suyan Liu, Xiaoxia Wei
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Breast
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977624000110
_version_ 1827310821730942976
author Huiting Lin
Wenhua Wu
Xiaoya Lou
Yiming Wang
Hong Sun
Jiaqin Cai
Suyan Liu
Xiaoxia Wei
author_facet Huiting Lin
Wenhua Wu
Xiaoya Lou
Yiming Wang
Hong Sun
Jiaqin Cai
Suyan Liu
Xiaoxia Wei
author_sort Huiting Lin
collection DOAJ
description Background: Circulating tumor cell (CTC) counting may be a useful non-invasive biomarker that helps patients choose first-line treatment options. Nevertheless, the cost of CTC inspection may impose an economic burden on patients, necessitating the simultaneous consideration of both its clinical effectiveness and cost. We evaluated the cost-effectiveness of CTC count-guided chemotherapy and endocrine therapy as first-line therapy for HR+/HER2-metastatic breast cancer (MBC) from the perspective of US payers. Methods: Based on the STIC CTC trial, a Markov model was constructed for three health states, and health outcomes were measured in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were performed to assess the robustness of the incremental cost per QALY. Results: The base-case analysis revealed that CTC count-driven treatment was associated with improved effectiveness by 0.07 QALYs and increased the overall cost by $9187.05 compared with clinician-driven first-line treatment choices, leading to an ICER of $138 354.15 per QALY. One-way sensitivity analysis indicated that the model was most sensitive to the cost of treatment for neutropenia and the utility for PFS; probability sensitivity analysis indicated that CTC count-driven treatment choices would be considered the cost-effective option at a willingness-to-pay threshold of $150 000 per QALY. Conclusions: The findings of this cost-effectiveness analysis suggest that, at the current price of CTC enumeration, choosing first-line treatment options based on CTC count is a cost-effectiveness approach for treating patients with HR+/HER2- MBC in the US.
first_indexed 2024-03-08T00:24:20Z
format Article
id doaj.art-e80d477560374b6bb95f5d890d62692b
institution Directory Open Access Journal
issn 1532-3080
language English
last_indexed 2024-04-24T20:07:14Z
publishDate 2024-04-01
publisher Elsevier
record_format Article
series Breast
spelling doaj.art-e80d477560374b6bb95f5d890d62692b2024-03-24T06:56:31ZengElsevierBreast1532-30802024-04-0174103680Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?Huiting Lin0Wenhua Wu1Xiaoya Lou2Yiming Wang3Hong Sun4Jiaqin Cai5Suyan Liu6Xiaoxia Wei7Fujian Medical University, School of Pharmacy, Fuzhou, Fujian, 350004, PR China; Shengli Clinical Medical College of Fujian Medical University, Fujian Province Hospital, Department of Pharmacy, Fuzhou, Fujian, 350001, PR ChinaFujian Medical University, School of Pharmacy, Fuzhou, Fujian, 350004, PR China; Shengli Clinical Medical College of Fujian Medical University, Fujian Province Hospital, Department of Pharmacy, Fuzhou, Fujian, 350001, PR ChinaThe First Hospital of Changsha City, Affiliated Changsha Hospital of XiangYa School of Medicine, CSU, Changsha, Hunan, 410000, PR ChinaShengli Clinical Medical College of Fujian Medical University, Fujian Province Hospital, Department of Pharmacy, Fuzhou, Fujian, 350001, PR China; Fujian University of Traditional Chinese Medicine, School of Pharmacy, Fuzhou, Fujian, 350122, PR ChinaShengli Clinical Medical College of Fujian Medical University, Fujian Province Hospital, Department of Pharmacy, Fuzhou, Fujian, 350001, PR ChinaShengli Clinical Medical College of Fujian Medical University, Fujian Province Hospital, Department of Pharmacy, Fuzhou, Fujian, 350001, PR ChinaShengli Clinical Medical College of Fujian Medical University, Fujian Province Hospital, Department of Pharmacy, Fuzhou, Fujian, 350001, PR China; Fujian University of Traditional Chinese Medicine, School of Pharmacy, Fuzhou, Fujian, 350122, PR ChinaShengli Clinical Medical College of Fujian Medical University, Fujian Province Hospital, Department of Pharmacy, Fuzhou, Fujian, 350001, PR China; Corresponding author. Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, PR China.Background: Circulating tumor cell (CTC) counting may be a useful non-invasive biomarker that helps patients choose first-line treatment options. Nevertheless, the cost of CTC inspection may impose an economic burden on patients, necessitating the simultaneous consideration of both its clinical effectiveness and cost. We evaluated the cost-effectiveness of CTC count-guided chemotherapy and endocrine therapy as first-line therapy for HR+/HER2-metastatic breast cancer (MBC) from the perspective of US payers. Methods: Based on the STIC CTC trial, a Markov model was constructed for three health states, and health outcomes were measured in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were performed to assess the robustness of the incremental cost per QALY. Results: The base-case analysis revealed that CTC count-driven treatment was associated with improved effectiveness by 0.07 QALYs and increased the overall cost by $9187.05 compared with clinician-driven first-line treatment choices, leading to an ICER of $138 354.15 per QALY. One-way sensitivity analysis indicated that the model was most sensitive to the cost of treatment for neutropenia and the utility for PFS; probability sensitivity analysis indicated that CTC count-driven treatment choices would be considered the cost-effective option at a willingness-to-pay threshold of $150 000 per QALY. Conclusions: The findings of this cost-effectiveness analysis suggest that, at the current price of CTC enumeration, choosing first-line treatment options based on CTC count is a cost-effectiveness approach for treating patients with HR+/HER2- MBC in the US.http://www.sciencedirect.com/science/article/pii/S0960977624000110Circulating tumor cellCost-effectiveness analysisBreast cancerMarkov model
spellingShingle Huiting Lin
Wenhua Wu
Xiaoya Lou
Yiming Wang
Hong Sun
Jiaqin Cai
Suyan Liu
Xiaoxia Wei
Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?
Breast
Circulating tumor cell
Cost-effectiveness analysis
Breast cancer
Markov model
title Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?
title_full Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?
title_fullStr Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?
title_full_unstemmed Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?
title_short Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?
title_sort is circulating tumor cell count driven cost effective for first line therapy choice in hr her2 metastatic breast cancer in the united states
topic Circulating tumor cell
Cost-effectiveness analysis
Breast cancer
Markov model
url http://www.sciencedirect.com/science/article/pii/S0960977624000110
work_keys_str_mv AT huitinglin iscirculatingtumorcellcountdrivencosteffectiveforfirstlinetherapychoiceinhrher2metastaticbreastcancerintheunitedstates
AT wenhuawu iscirculatingtumorcellcountdrivencosteffectiveforfirstlinetherapychoiceinhrher2metastaticbreastcancerintheunitedstates
AT xiaoyalou iscirculatingtumorcellcountdrivencosteffectiveforfirstlinetherapychoiceinhrher2metastaticbreastcancerintheunitedstates
AT yimingwang iscirculatingtumorcellcountdrivencosteffectiveforfirstlinetherapychoiceinhrher2metastaticbreastcancerintheunitedstates
AT hongsun iscirculatingtumorcellcountdrivencosteffectiveforfirstlinetherapychoiceinhrher2metastaticbreastcancerintheunitedstates
AT jiaqincai iscirculatingtumorcellcountdrivencosteffectiveforfirstlinetherapychoiceinhrher2metastaticbreastcancerintheunitedstates
AT suyanliu iscirculatingtumorcellcountdrivencosteffectiveforfirstlinetherapychoiceinhrher2metastaticbreastcancerintheunitedstates
AT xiaoxiawei iscirculatingtumorcellcountdrivencosteffectiveforfirstlinetherapychoiceinhrher2metastaticbreastcancerintheunitedstates